#4515. Trends of pharmaceutical corporations’ external innovation strategies: An inverse sigmoid curve

August 2026publication date
Proposal available till 16-05-2025
4 total number of authors per manuscript0 $

The title of the journal is available only for the authors who have already paid for
Journal’s subject area:
Sociology and Political Science;
Education;
Business and International Management;
Human Factors and Ergonomics;
Places in the authors’ list:
place 1place 2place 3place 4
FreeFreeFreeFree
2350 $1200 $1050 $900 $
Contract №4515.1 Contract №4515.2 Contract №4515.3 Contract №4515.4
1 place - free (for sale)
2 place - free (for sale)
3 place - free (for sale)
4 place - free (for sale)

More details about the manuscript: Science Citation Index Expanded or/and Social Sciences Citation Index
Abstract:
For decades, scholars believe major pharmaceutical corporations have been facing a decline in R&D efficiency, leading to an increasing demand for early-stage (R&D stage) external innovation. However, after outlining pharmaceutical corporations’ demands on external innovation toolkits by an inverse sigmoid curve, this research indicates an increasing focus of major players on late-stage (commercial or late-development stage) external innovation. Initial results deliver a potential strategy that transferring external innovation focus in advance for R&D excellence, and also suggests policy-makers provide further platforms for enhancing external innovation ecosystem in the pharmaceutical industry.
Keywords:
Drug discovery; External research; Open innovation; Pharmaceutical industry; Technology management

Contacts :
0